NTRK1 and prostate cancer: For example, in PC3-LN4 prostate cancer cells, intrinsic resistance to both allosteric and ATP-competitive AKTis has been demonstrated to involve AKTi-induced PIM1 upregulation followed by a PIM1-dependent increase in receptor tyrosine kinase expression via cap-independent translation51.